Episurf Medical: FDA approval for the patellofemoral system – a huge step for Episurf - Redeye

Redeye is encouraged by the FDA approval for Episurf Medical’s patellofemoral system product and argues that 2023 will be an exciting year to see the company advancing in the US. The share is currently trading with a +100% upside to our SEK5.0 base case, which we leave untouched following the news.

Länk till analysen i sin helhet: https://www.redeye.se/research/870121/episurf-medical-fda-approval-for-the-patellofemoral-system-a-huge-step-for-episurf?utm_source=finwire&utm_medium=RSS